This is a preview of subscription content, log in via an institution to check access.
References
Poirel H, Radford-Weiss I, Rack K, Troussard X, Veil A, Valensi F et al. Detection of the chromosome 16 CBF beta-MYH11 fusion transcript in myelomonocytic leukemias. Blood 1995; 85: 1313–1322.
Mrozek K, Heinonen K, Bloomfield CD . Prognostic value of cytogenetic findings in adults with acute myeloid leukemia. Int J Hematol 2000; 72: 261–271.
Buonamici S, Ottaviani E, Testoni N, Montefusco V, Visani G, Bonifazi F et al. Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state. Blood 2002; 99: 443–449.
Schnittger S, Weisser M, Schoch C, Hiddemann W, Haferlach T, Kern W . New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFB-MYH11+ acute myeloid leukemia based on quantification of fusion transcripts. Blood 2003; 102: 2746–2755.
Tobal K, Newton J, Macheta M, Chang J, Morgenstern G, Evans PA et al. Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in durable remission and predict clinical relapse. Blood 2000; 95: 815–819.
Leroy H, Botton SD, Grardel-Duflos N, Darre S, Leleu X, Roumier C et al. Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8;21). Leukemia 2005; 19: 367–372.
Gallagher RE, Yeap BY, Bi W, Livak KJ, Beaubier N, Rao S et al. Quantitative real-time RT-PCR analysis of PML-RARalpha mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129. Blood 2003; 101: 2521–2528.
Gabert J, Beillard E, van der Velden VHJ, Bi W, Grimwade D, Pallisgaard N et al. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction (RQ-PCR) of fusion gene transcripts for minimal residual disease detection in leukemia – A Europe Against Cancer Program. Leukemia 2003; 12: 2318–2357.
Lo-Coco F, Breccia M, Diverio D . The importance of molecular monitoring in acute promyelocytic leukaemia. Best Pract Res Clin Haematol 2003; 16: 503–520.
Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995; 86: 2041–2050.
Acknowledgements
We are grateful to Professor Dr N Blanckaert for this continuous support and to Marieke Comans-Bitter for preparation of the figures.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Boeckx, N., De Roover, J., van der Velden, V. et al. Quantification of CBFB-MYH11 fusion gene levels in paired peripheral blood and bone marrow samples by real-time PCR. Leukemia 19, 1988–1990 (2005). https://doi.org/10.1038/sj.leu.2403961
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2403961
- Springer Nature Limited
This article is cited by
-
Use of Minimal Residual Disease in Acute Myeloid Leukemia Therapy
Current Treatment Options in Oncology (2020)
-
Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemia
Leukemia (2016)
-
CBFB–MYH11/RUNX1 together with a compendium of hematopoietic regulators, chromatin modifiers and basal transcription factors occupies self-renewal genes in inv(16) acute myeloid leukemia
Leukemia (2014)
-
Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol
Leukemia (2010)